---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-245102"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T03:02:31.448658+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alector's Phase 3 latozinemab trial fails; workforce cut 49%, R&D head resigns

## Summary
- Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed clinical co-primary endpoint; biomarker endpoint met but no treatment effects seen.
- Workforce reduction of ~49% (about 75 employees); restructuring charges ~$7.7M; completion expected by H1 2026.
- President and Head of R&D Sara Kenkare-Mitra resigns effective Dec 22, 2025; separation includes 9 months salary and 50% bonus.
- Preliminary cash, equivalents, and short-term investments ~$291.1M as of Sep 30, 2025; runway expected through 2027.

## SEC filing metadata
- accession: 0001193125-25-245102
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/0001193125-25-245102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/alec-20251020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-245102
- JSON: https://secwatch.observer/filing/0001193125-25-245102.json
- Plain text: https://secwatch.observer/filing/0001193125-25-245102.txt

## Key facts
- Restructurings & Charges
  Alector, Inc. announced a restructuring with charges of approximately $7.7 million affecting across the organization (approximately 75 employees).
  - Type: restructuring
  - Charge: approximately $7.7 million
  - Affected area: across the organization
  - Headcount: approximately 75 employees
  source text: The Company initiated a reduction in force impacting approximately 75 employees across the organization. Total incremental restructuring charges associated with the reduction in force are expected to be approximately $7.7 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/0001193125-25-245102-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.